Maintenance of cognitive performance and mood for individuals with Alzheimer's disease following consumption of a nutraceutical formulation: A one-year, open-label study

Journal of Alzheimer's Disease

Volumn 51, Issue 4, 2016, Pages 991-995

  Remington, Ruth ^a,b   Bechtel, Cynthia ^b   Larsen, David ^c   Samar, Annemarie ^b,d   Page, Robert ^b   Morrell, Christopher ^e   Shea, Thomas B ^a,f  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b FRAMINGHAM STATE UNIVERSITY   (United States)

^c Advanced Memory Dynamics   (United States)

^d WORCESTER STATE UNIVERSITY   (United States)

^e LOYOLA UNIVERSITY MARYLAND   (United States)

^f University of Massachusetts Lowell   (United States)

Author keywords

Alzheimer's disease; behavioral symptoms; cognitive performance; mood; nutraceutical formulation

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CYANOCOBALAMIN; FOLIC ACID; LEVACECARNINE; S ADENOSYLMETHIONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION ASSESSMENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DRUG EFFICACY; DRUG FORMULATION; DRUG USE; HUMAN; MOOD; OPEN STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; COGNITION DISORDERS; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE COURSE; FEMALE; FOLLOW UP; MALE; MOOD DISORDERS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ALZHEIMER DISEASE; COGNITION DISORDERS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; MALE; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; VITAMIN B 12;

EID: 84964812472     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151098     Document Type: Article

References (37)

1. Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, Baumgart M, Banerjee S, Beck C, Blennow K, Brookmeyer R, Brunden KR, Buckwalter KC, Comer M, Covinsky K, Feinberg LF, Frisoni G, Green C, Guimaraes RM, Gwyther LP, Hefti FF, Hutton M, Kawas C, Kent DM, Kuller L, Langa KM, Mahley RW, Maslow K, Masters CL, Meier DE, Neumann PJ, Paul SM, Petersen RC, Sager MA, Sano M, Schenk D, Soares H, Sperling RA, Stahl SM, van Deerlin V, Stern Y, Weir D, Wolk DA, Trojanowski JQ (2012) Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 8, 445 - 452.
2. Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M (2011) The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia. Rev Neurol Paris 168, 471 - 482.
3. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337, 1488 - 1492.
4. Shea TB, Rogers E, Remington R (2012) Nutrition and dementia: Are we asking the right questions?.J Alzheimers Dis 28, 423 - 431.
5. Morris MC, Tangney CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305, 1348 - 1349.
6. Chan A, Paskavitz J, Remington R, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A one-year open-label pilot study with a 16-month extension. Am J Alz Dis Other Dementias 23, 571 - 585.
7. Remington R, Chan A, Shea TB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate to late-stage Alzheimer's disease: A placebo-controlled pilot study. Am J Alz Dis Other Dement 24, 27 - 33.
8. Remington R, Bechtel C, Larsen D, Lortie JJ, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Hoffmann H, Barysauskas C, Barton B, Shea TB (2015) A nutritional formulation for cognitive performance and mood in Alzheimer's disease: A phase II multi-site randomized trial with an open-label extension.J Alzheimers Dis 45, 395 - 405.
9. Remington R, Lortie J, Hoffman H, Page R, Morrell C, Shea TB (2015) A nutritional formulation for cognitive performance in mild cognitive impairment: A placebo-controlled trial with an open-label extension.J Alzheimers Dis 48, 591 - 595.
10. Chan A, Lepore A, Kotoya E, Zemianek J, Remington R, Shea TB (2010) Efficacy of a vitamin/nutriceutical formulation on cognitive speed and recall in adults with no known or suspected dementia.J Nutri Health Aging 14, 224 - 230.
11. Mischoulon D, Fava M (2002) Role of S-adenosyl-L methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 76 11158S - 1161S.
12. Royall DR, Cordes JA, Polk M (1998) CLOX: An executive clock drawing test.J Neurol Neurosurg Psychiatry 64, 588 - 594.
13. Monsch AU, Bondi MW, Salmon DP, Butters N, Thal LJ, Hansen LA, Wiederholt WC, Cahn DA, Klauber MR (1995) Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double crossvalidation and application to a community-dwelling sample. Arch Neurol 52, 899 - 904.
14. Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients.Neurology 48, S10 - S16.
15. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11, S33 - S39.
16. Cohen J (1992) A power primer.Psychol Bull 112, 155 - 159.
17. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative, Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819 - 2826.
18. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13, 43 - 54.
19. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT (1999) The effects of donepezil in Alzheimer's disease- results from a multinational trial. Dementia Geriatr Cogn Disord 10, 237 - 244.
20. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32, 1538 - 1544.
21. Corey-Bloom J, Anand R, Veach J (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1, 55 - 65.
22. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, dimebon investigators (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372, 207 - 215.
23. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311, 33 - 44.
24. Forette F, Anand R, Gharabawi G (1999) A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine. Eur J Neurol 6, 423 - 429.
25. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH (2000) Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol 57, 94 - 99.
26. Homma A1, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T (2000) Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dementia Geriatr Cog Disord 11, 299 - 313.
27. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6- month extension.Neurology 54, 2261 - 2268.
28. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease.Neurology 50, 136 - 145.
29. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R (2007) A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22, 456 - 467.
30. Royall DR (2014) Towards an aging-specific cognitive phenotype: The Freedom House Study. Exp Aging Res 40, 245 - 265.
31. Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis.J Alzheimers Dis 41, 615 - 631.
32. Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease.J Alzheimers Dis 38, 111 - 120.
33. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, Alzheimer's Disease Working Group (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39 - 53.
34. Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R (2013) Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database.J Alzheimers Dis 37, 173 - 183.
35. Safouris A, Tsivgoulis G, Sergentanis TN, Psaltopoulou T (2015) Mediterranean diet and risk of dementia.∗Curr Alzheimer Res 12, 736 - 744.
36. Chan A, Tchantchou F, Graves V, Rozen R, Shea TB (2008) Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: Critical role of S-adenosylmethionine.J Health Nutr Aging 12, 252 - 261.
37. Cornelli U (2010) Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis 7, 193 - 202.